Approval · Notice of Compliance 3184 · 1998
SEREVENT: Notice of Compliance 3184
Issued November 20, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3184
- Date
- November 20, 1998
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment of chronic obstructive pulmonary disease
- Therapeutic class
- BRONCHODILATOR (ß2-ADRENERGIC STIMULANT)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEREVENT | Not yet assigned | — |
Medicinal ingredients
- SALMETEROL XINAFOATE 25 MCG per ACT
- SALMETEROL XINAFOATE 50 MCG per ACT